A review on precision medicine and conducting pharmacogenetics tests of drugs

References

• 1.
  Payne K, Annemans L. Reflections on market access for personalized medicine: recommendations for Europe. Value Health 2013; 16: S32-S38.
• 2.
  Janiaud P, Serghiou S, Ioannidis JP. New clinical trial designs in the era of precision medicine: an overview of definitions, strengths, weaknesses, and current use in oncology. Cancer Treat Rev 2019; 73: 20-30.
• 3.
  Faulkner E, Annemans L, Garrison L, Helfand M, Holtorf A-P, Hornberger J, et al. Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR Personalized Medicine Special Interest Group. Value Health 2012; 15: 1162-1171.
• 4.
  Food UJ. Master protocols: efficient clinical trial design strategies to expedite development of oncology drugs and biologics. Guidance Indust 2018.
• 5.
  Redekop WK, Mladsi D. The faces of personalized medicine: a framework for understanding its meaning and scope. Value Health 2013; 16: S4-S9.
• 6.
  Groessl EJ, Tally SR, Hillery N, Maciel A, Garces JA. Cost-effectiveness of a pharmacogenetic test to guide treatment for major depressive disorder. J Manag Care Spec Pharm 2018; 24: 726-734.
• 7.
  Verbelen M, Weale ME, Lewis CM. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet? Pharmacogenomics J 2017; 17: 395-402.
• 8.
  https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling.
• 9.
  https://www.fda.gov.ir/fa//---.
• 10.
  Marques FB, Penedones A, Mendes D, Alves C. A systematic review of observational studies evaluating costs of adverse drug reactions. Clinicoecon Outcomes Res 2016; 8: 413.
• 11.
  Collins SL, Carr DF, Pirmohamed M. Advances in the Pharmacogenomics of Adverse Drug Reactions. Drug Safety 2016; 39: 15-27.
• 12.
  Amin AM, Chin LS, Azri Mohamed Noor D, SK Abdul Kader MA, Kah Hay Y, Ibrahim B. The personalization of clopidogrel antiplatelet therapy: the role of integrative pharmacogenetics and pharmacometabolomics. Cardiol Res Pract 2017; 2017.
• 13.
  Groessl EJ, Tally SR, Hillery N, Maciel A, Garces JA. Cost-effectiveness of a pharmacogenetic test to guide treatment for major depressive disorder. J Manag Care Spec Pharm 2018; 24: 726-734.
• 14.
  Alagoz O, Durham D, Kasirajan K. Cost-effectiveness of one-time genetic testing to minimize lifetime adverse drug reactions. Pharmacogenomics J 2016; 16: 129-136.
• 15.
  Plothner M, Ribbentrop D, Hartman JP, Frank M. Cost-effectiveness of pharmacogenomic and pharmacogenetic test-guided personalized therapies: a systematic review of the approved Active substances for personalized medicine in Germany. Adv Ther 2016; 33: 1461-1480.##.